Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine

References

• LambertEHEatonLMRookeEDDefect of neuromuscular conduction associated with malignant neoplasmsAm J Physiol1956187612613
   Web of Science ®Google Scholar
• LambertEHElmqvistDQuantal components of end-plate potentials in the myasthenic syndromeAnn N Y Acad Sci19711831831994330759
   PubMed Web of Science ®Google Scholar
• O’NeillJHMurrayNMNewsom-DavisJThe Lambert–Eaton myasthenic syndrome. A review of 50 casesBrain1988111Pt 35775962838124
   PubMed Web of Science ®Google Scholar
• LangBNewsom-DavisJWrayDVincentAMurrayNAutoimmune aetiology for myasthenic (Eaton-Lambert) syndromeLancet198122242266114283
   PubMed Web of Science ®Google Scholar
• LangBNewsom-DavisJPriorCWrayDAntibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouseJ Physiol19833443353456655585
   PubMed Web of Science ®Google Scholar
• FukunagaHEngelAGLangBNewsom-DavisJVincentAPassive transfer of Lambert–Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zonesProc Natl Acad Sci U S A198380763676406584877
   PubMed Web of Science ®Google Scholar
• MotomuraMJohnstonILangBVincentANewsom-DavisJAn improved diagnostic assay for Lambert–Eaton myasthenic syndromeJ Neurol Neurosurg Psychiatry19955885877823075
   PubMed Web of Science ®Google Scholar
• LennonVAKryzerTJGriesmannGECalcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromesN Engl J Med1995332146714747739683
   PubMed Web of Science ®Google Scholar
• LangBNewsom-DavisJPeersCPriorCWrayDWThe effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouseJ Physiol19873902572702450991
   PubMed Web of Science ®Google Scholar
• TakamoriMLambert–Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasisJ Neuroimmunol2008201202145152
   Web of Science ®Google Scholar
• O’SuilleabhainPLowPALennonVAAutonomic dysfunction in the Lambert–Eaton myasthenic syndrome: Serologic and clinical correlatesNeurology19985088939443463
   PubMed Web of Science ®Google Scholar
• WatermanSAAutonomic dysfunction in Lambert–Eaton myasthenic syndromeClin Auton Res20011114515411605819
   PubMed Web of Science ®Google Scholar
• TitulaerMJWirtzPWKuksJBThe Lambert-Eaton myasthenic syndrome 1988–2008. A clinical picture in 97 patientsJ Neuroimmunol2008201202153158
   Web of Science ®Google Scholar
• TitulaerMJVerschuurenJJLambert–Eaton myasthenic syndrome: Tumor versus nontumor formsAnn N Y Acad Sci2008113212913418567862
   PubMed Web of Science ®Google Scholar
• TitulaerMJMaddisonPSontJKClinical Dutch-English Lambert–Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMSJ Clin Oncol20112990290821245427
   PubMed Web of Science ®Google Scholar
• TitulaerMJSoffiettiRDalmauJScreening for tumours in paraneoplastic syndromes: Report of an EFNS task forceEur J Neurol20111819-e320880069
   PubMed Web of Science ®Google Scholar
• FarrugiaMEVincentAAutoimmune mediated neuromuscular junction defectsCurr Opin Neurol20102348949520651592
   PubMed Web of Science ®Google Scholar
• BainPGMotomuraMNewsom-DavisJEffects of intravenous immunoglobulin on muscle weakness and calcium-channel autoan-tibodies in the Lambert–Eaton myasthenic syndromeNeurology1996476786838797464
   PubMed Web of Science ®Google Scholar
• SkeieGOApostolskiSEvoliAGuidelines for treatment of autoimmune neuromuscular transmission disordersEur J Neurol20101789390220402760
   PubMed Web of Science ®Google Scholar
• AndersonHJChurchill-DavidsonHCRichardsonATBronchial neoplasm with myasthenia: Prolonged apnoea after administration of succinylcholineLancet19532651291129313110148
   PubMed Web of Science ®Google Scholar
• VerschuurenJJWirtzPWTitulaerMJWillemsLNvan GervenJAvailable treatment options for the management of Lambert–Eaton myas-thenic syndromeExpert Opin Pharmacother200671323133616805718
   PubMedGoogle Scholar
• WirtzPWVerschuurenJJvan DijkJGEfficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: A randomized, double-blind, placebo-controlled, crossover studyClin Pharmacol Ther200986444819357643
   PubMed Web of Science ®Google Scholar
• LambertEHDefects of neuromuscular transmission in syndromes other than myasthenia gravisAnn N Y Acad Sci19661353673845221351
   PubMed Web of Science ®Google Scholar
• LemeignanMMillartHLamiableDMolgoJLechatPEvaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cere-brospinal fluid in anesthetized ratsBrain Res19843041661696744035
   PubMed Web of Science ®Google Scholar
• MolgóJLundhHThesleffSPotency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changesEur J Pharmacol19806125346101553
   PubMed Web of Science ®Google Scholar
• HuangHYHerttingGAllgaierCJackischR3,4-Diaminopyridine-induced noradrenaline release from CNS tissue as a model for action potential-evoked transmitter release: Effects of phorbol esterEur J Pharmacol19891691151232574686
   PubMed Web of Science ®Google Scholar
• MaddisonPNewsom-DavisJMillsKREffect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert–Eaton myasthenic syndromeMuscle Nerve199821119611989703446
   PubMed Web of Science ®Google Scholar
• HongSJChangCCFacilitation by 3,4-diaminopyridine of regenerative acetylcholine release from mouse motor nerveBr J Pharmacol19901017937981964819
   PubMed Web of Science ®Google Scholar
• BragaMFHarveyALRowanEGEffects of tacrine, velna-crine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on sceletal neuromuscular transmission in vitroBr J Pharmacol19911029099151649660
   PubMed Web of Science ®Google Scholar
• Van LunterenEMoyerMElectrophysiologic and inotropic effects of K+ channel blockade in aged diaphragmAm J Respir Crit Care Med19981588208269731011
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment report for Zenas® Procedure No. EMEA/H/C/001032. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001032/WC500069918.pdfLondon, UKEuropean Medicines Agency2009
   Google Scholar
• QuartelATurbevilleSLounsburyDCurrent therapy for Lambert–Eaton myasthenic syndrome: Development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatmentCurr Med Res Opin2010261363137520377318
   PubMed Web of Science ®Google Scholar
• SandersDB3,4-Diaminopyridine (DAP) in the treatment of Lambert–Eaton myasthenic syndrome (LEMS)Ann N Y Acad Sci19988418118169668334
   PubMed Web of Science ®Google Scholar
• LundhHNilssonORosénINovel drug of choice in Eaton–Lambert syndromeJ Neurol Neurosurg Psychiatry1983466846856310051
   PubMed Web of Science ®Google Scholar
• McEvoyKMWindebankAJDaubeJRLowPA3,4-diaminopyridine in the treatment of Lambert–Eaton myasthenic syndromeNew Engl J Med1989321156715712555713
   PubMed Web of Science ®Google Scholar
• SandersDBMasseyJMSandersLLEdwardsLJA randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndromeNeurology20005460360710680790
   PubMed Web of Science ®Google Scholar
• OhSJClaussenGGHatanakaYMorganMB3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMSMuscle Nerve20094079580019722254
   PubMed Web of Science ®Google Scholar
• KeoghMSedehizadehKHMaddisonPTreatment for Lambert–Eaton myasthenic syndromeCochrane Database Syst Rev20112CD00327921328260
   PubMed Web of Science ®Google Scholar
• LundhHNilssonORosénITreatment of Lambert–Eaton syndrome: 3,4-diaminopyridine and pyridostigmineNeurology198434132413306541305
   PubMed Web of Science ®Google Scholar
• SatohKMotomuraMSuzuHNeurogenic bladder in Lambert–Eaton myasthenic syndrome and its reponse to 3,4-diaminopyridineClin Auton Res20011114515411605819
   PubMed Web of Science ®Google Scholar
• BoermaCERommesJHvan LeeuwenRBBakkerJCardiac arrest following a iatrogenic by 3,4-diaminopyridine intoxication in a patient with Lambert–Eaton myasthenic syndromeJ Toxicol Clin Toxicol1995332492517760450
   PubMed Web of Science ®Google Scholar
• LundhHNilssonORosenIJohanssonSPractical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndromeActa Neurol Scand1993881361408213058
   PubMed Web of Science ®Google Scholar
• WirtzPWTitulaerMJGervenJMVerschuurenJJ3,4-diaminopyridine for the treatment of Lambert–Eaton myasthenic syndromeExpert Rev Clin Immunol2010686787420979551
   PubMed Web of Science ®Google Scholar
• FletLPolardEGuillardO3,4-Diaminopyridine safety in clinical practice: An observational, retrospective cohort studyJ Neurol201025793794620058019
   PubMed Web of Science ®Google Scholar